Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach
Rainer König1,2,3, Xueqi Cao1,2,3, Marcus Oswald1,2,3
1Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.
Background:
The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available ex ante to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient.
Methods:
We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival.
Results:
We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48-2.27; p<0.001) compared to the observed standard of care.
Conclusion:
Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine.
Insights
A new decision tree identifies patients with moderate community-acquired pneumonia (CAP) who benefit from macrolide treatment. This personalized approach may reduce mortality by 27% in CAP patients.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- The use of macrolide/β-lactam combination therapy for moderate community-acquired pneumonia (CAP) is debated.
- Macrolides offer broader coverage and anti-inflammatory effects but carry risks of cardiovascular toxicity and drug interactions.
- Personalized treatment decisions are needed to optimize clinical outcomes for individual CAP patients.
Purpose of the Study:
- To develop a predictive decision tree for macrolide use in moderate CAP.
- To identify patient characteristics that predict benefit from macrolide/β-lactam combination therapy.
- To improve 180-day survival outcomes in hospitalized CAP patients.
Main Methods:
- Machine learning and cross-validation were applied to a large dataset (6440 patients) from the CAPNETZ study.
- Propensity score matching was used to create a well-balanced cohort of 4898 patients.
- The model utilized admission data, including aetiological and clinical parameters.
Main Results:
- A simple decision tree identified patient subgroups benefiting from macrolide treatment.
- Key predictors included chronic cardiovascular/respiratory comorbidities and leukocyte counts in respiratory secretions.
- Patients treated according to the decision rule showed a 27% lower mortality rate (OR 1.83).
Conclusions:
- Stratifying macrolide treatment based on a simple rule can significantly reduce CAP mortality.
- The developed decision tree offers a personalized approach to macrolide therapy in CAP.
- Further validation through a randomized controlled trial is recommended before clinical implementation.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: